Patricia Carr - 05 Dec 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
SVP, Chief Accounting Officer
Signature
By: /s/Paz Dizon, as attorney in fact For: Patricia Carr
Issuer symbol
JAZZ
Transactions as of
05 Dec 2025
Net transactions value
-$164,768
Form type
4
Filing time
09 Dec 2025, 17:25:20 UTC
Previous filing
20 Nov 2025
Next filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Carr Patricia SVP, Chief Accounting Officer 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND By: /s/Paz Dizon, as attorney in fact For: Patricia Carr 09 Dec 2025 0001784606

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Sale $27,378 -160 -2.2% $171.11 7,012 05 Dec 2025 Direct F1
transaction JAZZ Ordinary Shares Options Exercise $633,015 +4,500 +64% $140.67 11,512 05 Dec 2025 Direct
transaction JAZZ Ordinary Shares Sale $770,405 -4,500 -39% $171.20 7,012 05 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -4,500 -100% $0.000000 0 05 Dec 2025 Ordinary Shares 4,500 $140.67 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person acquired 160 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.
F2 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $171.2001 to $171.2601. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option fully vested as of March 1, 2022.